Global genomics in cancer care market is expected to reach USD
9.22 billion by 2022, according to a new report by Grand View Research, Inc.
Increasing prevalence of cancer coupled with adoption of next generation
sequencing for the diagnosis & treatment is expected to fuel the market
with future growth opportunities. Increasing incidences of cancer triggers the
demand for cost effective and accurate diagnostics in coming years.
In addition, increasing demand for personalized medicines in
molecular characterization of cancer to identify therapeutic targets is the
factor attributing towards the market growth. Similarly, factors such as cost
reduction in genome sequencing, growing healthcare expenditure levels and
development of effective diagnostics & therapeutic procedures for cancer
are responsible for the potential growth of genomics in cancer care.
Request to Sample
of This Report @ http://www.grandviewresearch.com/industry-analysis/genomics-in-cancer-care-market
Further key findings from the study suggest:
- Instrument segment dominated the overall market in terms of revenue share as of 2014 and accounted for 33.4% of market owing to high cost associated with it. Whereas, consumables are most widely used product segment in genome testing as they are indispensible component and frequently required to perform the test.
- Demand for services such as next generation sequencing, PCR and other such as cancer risk management & genetic testing are expected to grow over the forecast period due to increasing outsourcing activities to perform genome analysis. High cost of performing genetic tests and growing awareness pertaining to associated benefits with the use of these technologies are high impact rendering drivers for this segment.
- Drug discovery and development segment is expected to show lucrative CAGR of 17.6% during the forecast period owing to increasing demand for effective treatment for cancer and growing investment in biomedicines by manufacturers for the development of novel products.
- Genome sequencing held the dominant share of technology segment as it is most prominently used for diagnosis due to associate benefits such as faster and accurate method. It is expected to show significant growth rate of 17.5% in coming years owing to remarkable decrease in the cost for genome sequencing and increasing adoption rates.
- The cancer research segment held the largest share of 34.1% in 2014 due to increasing demand for faster & accurate diagnostic methods to treat variety of cancer. Other use such as commercial adoption of genetic testing is expected to be fastest growing segment owing to increasing demand of cancer genomic testing to fulfill unmet needs in healthcare sector.
- Some key players operating in this market include Beckman Coulter Inc., Illumina, Inc, Affymetrix, Roche Diagnostics, Agilent Technologies, Cancer Genetics Inc., Danaher Corporation, Bio-Rad Labs, Pacific Biosciences, Quest Diagnostics, Sigma Aldrich, Luminex, Thermo Fisher scientific, Oxford Gene Technology., PerkinElmer, Qiagen, and GE Healthcare.
To Get Sample Copy of Report visit
@ http://www.grandviewresearch.com/industry-analysis/genomics-in-cancer-care-market/request
About Grand View
Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For More Information,
Visit Grand
View Research
Contact:
Sherry James
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email:
sales@grandviewresearch.com
Blog Site: http://forecastresearchreport.blogspot.in/
No comments:
Post a Comment